explore -WSS

explore

author：knowledge 2025-09-14 18:24:43 - browse：2

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： DeSantis can now import cheaper drugs. But will Biden get credit?

WSS

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Bird flu outbreak in cows is latest avian flu curveball

Bird flu in milk supply is likely coming from asymptomatic cows

Biotech reporter’s notebook: A sunnier mood at JPM 2024

MultiPlan and major insurers sued for alleged medical price

The nurse manager staffing crisis is hurting patients

hotspot

explore

The next ALS data readout — overdue but important

knowledge

Virginia high school admissions case could be legal follow

Orangutan used medicinal plant to treat wound, first time ever seen

23andMe had bad news about my health. I wish a person had delivered it

JPM 2024: Nvidia claims we're in biological revolution. Are we?

After affirmative action ruling, medical educators look to 'holistic review'

Readout LOUD podcast: live from JPM 2024

Medicare details structure of new drug price negotiation program

Heart disease and mental health: A look at cardiac psychology

Hepatitis C has a cure — but many Americans still lack access to it

How I ended up pumping milk in a bathroom stall at JPM 2024

hotspot

Orangutan used medicinal plant to treat wound, first time ever seen

Q&A: Jennifer Adair on making gene therapy available globally

Designating disabled people as health disparity population is crucial

UnitedHealth financials solid despite Change Healthcare cyberattack

Three issues to watch in global health in 2024

Getting Alzheimer's drug Leqembi to patients can be a challenge

focus

entertainment

entertainment

entertainment